In-silico elucidation of phytoconstituents against 1LPB protein and anti-dyslipidaemic activity of Psoralea corylifolia Linn leaf extract

IF 1.8 Q3 PHARMACOLOGY & PHARMACY

Advances in Traditional Medicine Pub Date : 2022-11-09 DOI:10.1007/s13596-022-00671-1

Pushpa A. Karale, Shashikant C. Dhawale, Mahesh A. Karale

{"title":"In-silico elucidation of phytoconstituents against 1LPB protein and anti-dyslipidaemic activity of Psoralea corylifolia Linn leaf extract","authors":"Pushpa A. Karale, Shashikant C. Dhawale, Mahesh A. Karale","doi":"10.1007/s13596-022-00671-1","DOIUrl":null,"url":null,"abstract":"<div>Psoralea corylifolia L. has been used in traditional Chinese and Ayurvedic medicine systems for management of various diseases. The various phytochemical constituents work in orchestric manner to treat diverse illnesses. Current pharmaco-therapies shown beneficiary role in treatment of dyslipidaemia but facing life threatening side effects. The usage of herbs increased worldwide and paves the way for development of pharmaceuticals for hyperlipidemia treatment. The main objective of present work was to investigate anti-hyperlipidemic activity and in-silico pancreatic lipase inhibitory potential of Psoralea corylifolia L. (PC) leaf extract. The existence of several phytoconstituents was confirmed by the chromatographic research and mainly includes the flavonoids and furanocoumarins. All studied phytoconstituents were found to have superior binding affinity than standard orlistat (− 7.1 kcal/mol), with docking score ranges from − 10.6 to − 7.3 kcal/mol. At 200 mg/kg/day the ethanolic leaf extract demonstrated highest lipid lowering action. Ethanolic leaf extract of Psoralea corylifolia revealed evidential antihyperlipidemic potential in a concentration dependent manner (P < 0.01). The serum lipid profile (LDL, VLDL, TG, TC) dropped firmly and HDL elevated in hyperlipidemic rats treated with plant extract compared with the hyperlipidemic group rats (P < 0.01). The hepatic TC and TG abruptly increased in hyperlipidemic rats and significantly reduced in hyperlipidemic rats administered with EPC compared with the control group (P < 0.01). The hyperlipidemic rats treated with atorvastatin and PC at different doses shown evidentiary increase in secretion of TC and TG compared with the hyperlipidemic group rats. The study results proposed that EPC leaf extract demonstrated noteworthy antihyperlipidemic action. The findings of docking study recommend utilization of the best ligands experimentally to develop novel anti-obesity agents.</div>","PeriodicalId":7613,"journal":{"name":"Advances in Traditional Medicine","volume":"23 4","pages":"1185 - 1197"},"PeriodicalIF":1.8000,"publicationDate":"2022-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Traditional Medicine","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1007/s13596-022-00671-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 2

Abstract

Psoralea corylifolia L. has been used in traditional Chinese and Ayurvedic medicine systems for management of various diseases. The various phytochemical constituents work in orchestric manner to treat diverse illnesses. Current pharmaco-therapies shown beneficiary role in treatment of dyslipidaemia but facing life threatening side effects. The usage of herbs increased worldwide and paves the way for development of pharmaceuticals for hyperlipidemia treatment. The main objective of present work was to investigate anti-hyperlipidemic activity and in-silico pancreatic lipase inhibitory potential of Psoralea corylifolia L. (PC) leaf extract. The existence of several phytoconstituents was confirmed by the chromatographic research and mainly includes the flavonoids and furanocoumarins. All studied phytoconstituents were found to have superior binding affinity than standard orlistat (− 7.1 kcal/mol), with docking score ranges from − 10.6 to − 7.3 kcal/mol. At 200 mg/kg/day the ethanolic leaf extract demonstrated highest lipid lowering action. Ethanolic leaf extract of Psoralea corylifolia revealed evidential antihyperlipidemic potential in a concentration dependent manner (P < 0.01). The serum lipid profile (LDL, VLDL, TG, TC) dropped firmly and HDL elevated in hyperlipidemic rats treated with plant extract compared with the hyperlipidemic group rats (P < 0.01). The hepatic TC and TG abruptly increased in hyperlipidemic rats and significantly reduced in hyperlipidemic rats administered with EPC compared with the control group (P < 0.01). The hyperlipidemic rats treated with atorvastatin and PC at different doses shown evidentiary increase in secretion of TC and TG compared with the hyperlipidemic group rats. The study results proposed that EPC leaf extract demonstrated noteworthy antihyperlipidemic action. The findings of docking study recommend utilization of the best ligands experimentally to develop novel anti-obesity agents.

Abstract Image

查看原文本刊更多论文

补骨脂叶提取物抗1LPB蛋白的植物成分及抗血脂异常活性的计算机分析

补骨脂已被用于传统中医和阿育吠陀医学系统的各种疾病的管理。不同的植物化学成分协同作用，治疗不同的疾病。目前的药物治疗在治疗血脂异常中显示出有益的作用，但面临着危及生命的副作用。草药的使用在世界范围内增加，为开发治疗高脂血症的药物铺平了道路。本研究主要目的是研究补骨脂叶提取物的抗高脂血症活性和胰脂酶抑制潜能。通过色谱研究证实了几种植物成分的存在，主要包括类黄酮和呋喃香豆素。所有研究的植物成分都被发现具有比标准奥利司他(−7.1 kcal/mol)更高的结合亲和力，对接评分范围为−10.6至−7.3 kcal/mol。在200 mg/kg/天时，乙醇叶提取物表现出最高的降脂作用。补骨脂叶乙醇提取物显示出明显的降血脂潜能，且呈浓度依赖性(P < 0.01)。与高脂血症组大鼠相比，植物提取物组大鼠血脂(LDL、VLDL、TG、TC)下降明显，HDL升高(P < 0.01)。与对照组相比，给予EPC的高脂血症大鼠肝脏TC和TG显著升高，而给予EPC的高脂血症大鼠肝脏TC和TG显著降低(P < 0.01)。不同剂量阿托伐他汀和PC治疗的高脂血症大鼠与高脂血症组大鼠相比，TC和TG的分泌明显增加。研究结果表明，EPC叶提取物具有明显的降血脂作用。对接研究结果建议利用最佳配体实验开发新型抗肥胖药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Traditional Medicine PHARMACOLOGY & PHARMACY-

CiteScore

4.30

自引率

0.00%

发文量

期刊介绍： Advances in Traditional Medicine (ADTM) is an international and peer-reviewed journal and publishes a variety of articles including original researches, reviews, short communications, and case-reports. ADTM aims to bridging the gap between Traditional knowledge and medical advances. The journal focuses on publishing valid, relevant, and rigorous experimental research and clinical applications of Traditidnal Medicine as well as medical classics. At the same time, the journal is devoted to communication among basic researcher and medical clinician interested in the advancement of Traditional Medicine. Topics covered by the journal are: Medical Classics & History; Biomedical Research; Pharmacology & Toxicology of Natural Products; Acupuncture & Moxibustion; Sasang Constitutional Medicine; Diagnostics and Instrumental Development; Clinical Research. ADTM is published four times yearly. The publication date of this journal is 30th March, June, September, and December.